Mark Davison

Our portfolio company Seegnal e- Health, an Israeli digital Health provider, announces today that its distributor in the UK, Digitals UK, has been awarded a framework contract by the UK Government's Department of Health  to sell Seegnal's clinical decision-support software  platform (The digital virtual pharmacist)  in the UK health  public sector. As part of the tender won,. Seegnal through it's UK distrbutor, will be listed as part of a distinguished Clinical Decision Support systems list in Government buying platforms as of November 9, 2024. Digitals UK will be able to market, answer to bids, and deploy Seegnal as of November 9th in the UK public sector (NHS trusts, hospitals, and clinics) with anticipation of the first deployments to take place in 2025. We estimate the market potential for the tender, only in the public sector in the UK (excluding private hospitals and clinics), is estimated at over $50 million annually. Seegnal's parent company signed a definitive agreement with REEM Capital Corp. TSXV:REEM to list on the Toronto Stock Exchange Congratualtions Eyal Schneid and the Seegnal dedicated team for an excellent job !!! Shiri Guy Alfandary, PharmD. Timi Gilat, Adv. Jack Steckel Jonathan Held, CPA, CA Michael Saliken Jonathan Holmes Gadi Levin Yossi Boker

19

2 Comments

Key takeaway [for me] so far from this morning’s panel on how to balance patient-centric #digitaltherapeutics with scalable profitability can be summarised by the phrase “Build and they will come”. If you build a product that is intrinsically engaging and keeps patient adherent to the programme, then the clinical outcomes will show themselves, product value can be seen, and uptake will come and with it the money. And how to make a product engaging? For Hannes Klöpper of HelloBetter , it’s about getting patients involved as much as possible in the product development, get their feedback, use it to make necessary tweaks to improve the technology . No brainer? Are DTx companies already doing this? Other insights from Marek Ostrowski of Prosoma Kamran Adle Christian Lautner LSX - partnering for Life Science eXecutives #lsxworldcongress Laura Wamprecht

56

1 Comment

UK still naive on threats. Certain nations have embedded civil-military fusion in their private enterprises, are taught that industrial espionage is patriotic duty, take great pride in stealing technologies, and do not recognise arbitration. It is good to see this type of threat get more coverage in the emerging technology space - thanks Freya Pratty + Sifted

1

AIM ImmunoTech Implements Cash Conservation Strategy to Advance Ampligen Development AIM ImmunoTech Inc. has unveiled a cash conservation strategy to support its clinical trials and drug development initiatives, particularly focused on its flagship product, Ampligen. This initiative shifts compensation for independent directors entirely to stock and reduces the cash component of compensation for the CEO and COO. By doing so, AIM aims to reinforce its commitment to shareholder value while ensuring adequate resources to achieve critical milestones. Ampligen is being developed as a potential treatment for multiple serious conditions, including various cancers, immune disorders, and viral diseases. Adequate funding is vital for AIM’s ongoing research and development efforts, which could lead to groundbreaking treatments. The cash conservation strategy reflects the company’s determination to prioritize these efforts and enhance its long-term outlook. Key elements of the plan include transitioning independent board members to 100% stock-based compensation and reducing the cash portion of executive pay for the CEO and COO. Demonstrating confidence in AIM’s future, the CEO has purchased a substantial number of shares through the employee stock purchase plan and open market transactions. In contrast, nominees from the activist investor group have not made similar stock purchases. The company remains committed to advancing its clinical pipeline, with a strong focus on oncology. The board believes this area holds the greatest potential for creating long-term value for shareholders. This forward-thinking financial strategy underscores AIM ImmunoTech’s dedication to sustainable growth and innovation. By conserving cash and prioritizing critical research efforts, the company aims to achieve key clinical milestones, move closer to the commercialization of Ampligen, and potentially deliver transformative treatments for patients battling serious illnesses. 𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://lnkd.in/d6xgGSUX Peter Rodino III Ann Marie E. Coverly

1

Are you a manufacturer of Digital Therapeutics (DTx) with a focus on the UK market? In this blog post, we delve into the intricacies of Digital Therapeutics (DTx) regulation in the UK, especially in light of Brexit in January 2020. 👉 https://lnkd.in/eqYb38ZF #DTx #DigitalTherapeutics #RegulatoryAffairs #Brexit

11

Wow, Tempus AI will start trading today with a start price of $37/share giving it a market cap of $6B, raising over $400M. Great sign in my opinion for: - Element Biosciences: IPO market is open for good genomics stories. - Illumina: Tempus' primary NGS provider. - Companies in the genomics data + AI space: sets a new valuation level, there were very few prior exit stories above $100M. 👏👏👏

290

9 Comments

🎉Good news for UK start-ups🎉 - the Intellectual Property Office UK IP Audit and IP access funding schemes are back, with a bit of a make over 💄 See images below for details, and get in touch with your local advisor from the delivery partner s Innovate UK Scottish Enterprise Highlands and Islands Enterprise South of Scotland Enterprise Welsh Government and Invest Northern Ireland for more info - if you don't know who that is let me know and I'll try and find out! Key points ♥️IP AUDIT❤️ 💥You pay £750 inc VAT and gov pays £2,250 in VAT for a lovely and very useful, bespoke IP audit. Our clients have found these very useful, both for their own internal uses, and presenting their IP position to investors ❤️IP ACCESS♥️ 💥You get £2,250 in VAT towards the cost of some IP advice/work relevant to your business - you have to pay at least 50% total cost of that project. e.g. Towards from FTO works, or a new patent application 💥You can get this if ----you have identified something IP related you need to do during discussions with your advisor from one of the partner organisations ----you have been through the IP audit scheme in the last 12m and want to implement the recommendations ---you had an IP audit >12m ago, but recommendations still need implementing and there are reasons why you've not done it yet. So to get IP access, you don't need to have done an IP audit. But if you've done an IP audit and have things left to do (which I'm sure you all do!) - apply! If you want to chat IP - get in touch! #syntheticbiology #biotechnology #innovation #founders #postdoc #startups #phd

90

6 Comments

In a monumental move, Persephoni BioPartners and Loud Solutions have solidified a joint venture, creating a significant development for the scientific startup community in the North East. Persephoni BioPartners is a leading consultancy for early-stage Biotech companies. Supporting from Company Incorporation, IP & Legal, Strategic Advisory, Capital Raising to Commercialization. Loud Solutions is a boutique Human Capital consultancy focused entirely on the Pre-Seed to Series-B market place. Together they will find the best scientific assets and partner them with elite talent to maximize success and improve patient outcomes. Operating as the exclusive Human Capital provider for Persephoni BioPartners and its expansive portfolio, Loud Solutions brings a wealth of experience poised to deliver elite executive talent and cultivate a culture of sustainability and profitability. Redefining the standards of talent attraction and employee retention for startup and early stage assets. Thanks to Hilary Schultz and Willie for the work done over the past 3 months. "Putting the right people together, at the start, limits mistakes and improves the chances of success. Focused on improving patient outcomes and enabling innovation is always our priority." says Persephoni BioPartners Managing Partner and Cofounder Hilary Schultz See more here: https://lnkd.in/dGuvWwfu #jointventure #startups #partnership

35

9 Comments

Thank you Sophie Drinkwater, Senior Scientist in Microbiology at AstraZeneca and Jon Kallay, Senior Scientific Portfolio Specialist, Charles River Laboratories Microbial Solutions for presenting in yesterday's live webinar titled Building the House of Rapid Sterility – A Successful Platform Approach to introducing Rapid Methods If you missed this webinar, you can still watch it on demand https://lnkd.in/ezjr4M_K #Sterility #SterilityTesting #Validation #PharmaceuticalMicrobiology #RapidMicrobiologicalMethods #Biopharma #QualityControl #ATPBioluminescence #CFU #microorganismColonyForming #ATP #subculturing #solator #DirectInoculation #FiltrationTests #Isolator #PharmaceuticalProcess #Bioprocessing #ProcessValidation #CellTherapies #GeneTherapies #ATPBioluminescence #RapidSterility #ClosedFiltrationSystems #SterilityTestPump #ParenteralProducts #Pharmaceuticals #QC

1

Biotech Leaders, Take Note: Are Your Contracts Working for You? 🧬📊 Managing contract renewals might seem mundane, but in biotech, it’s the secret sauce to: 🚫 Avoiding project delays 📈 Scaling operations efficiently 🛡️ Staying compliant in a highly regulated environment It's time to stop letting contracts be a bottleneck and start using them as a lever for growth. In our latest article, we explore the game-changing strategies biotech firms are using to streamline operations through effective contract renewal management. Curious to see how your peers are staying ahead? 🔗 Dive into the insights https://lnkd.in/e_ADt_JE Let’s make contract management a growth driver, not a hurdle. What's one contract challenge you’ve faced recently? Share below!

14

Delighted to be invited to present & discuss managing #AMR with the ‘#CrossPartyParliamentGroupOnLifeSciences (#CPPGLS)’ at The Scottish Parliament about our #innovative disruptive offering from Microplate Dx Limited in tackling global challenge of #AntiMicrobialResistance in the ‘#WorldAntiMicrobialResistanceAwarenessWeek (#WAAW)’ 2024. Microplate Dx Limited #CoFounders: Dr Stuart Hannah (CEO & Director), Prof Damion Corrigan (CTO), Prof Paul Hoskisson (CSO) & I (Board Chair & Director)- met the #Parliamentarians & The Scottish Government executives & CPPG members. With a relentless drive to solve complex problems & improve efficiency- as #entrepreneurs we are harnessing the power of cutting-edge #technology-to create a #business that is pushing boundaries, disrupting #industries & revolutionising the way we work & live a healthy life. Microplate Dx Limited tackles the complex & global challenge of #AMR with a #Deeptech platform tech, providing a #diagnostic solution to aid clinician’s decision-making- Ultimately helping patients & societies globally. Our primary #purpose is to avoid #patients suffering & after-effects. Motivation is to support #clinicians/#Doctors & #healthcare organisations to prescribe the ‘right drug first time itself’ by choosing a correct #antibiotic. With that focus we strive to bring our #disruptive #product to the market to help #women, #elderly & #children and help reduce #AMR- related #deaths, suffering & save on costs. Some hard-hitting numbers: 1. 1 in 3 #Females at some point in their lifetime suffers from #Urinary #Tract #Infections (#UTIs), which requires an #antibiotic 2. With 65% of #Scotland/the #UK’s population approaching above 65 years age- UTI likelihood increases by 3-8%/day for #elderly residents with #Catheter. Microplate Dx Limited #team is continuing to work towards our goal despite perceived #barriers in #adoption & #implementation of #MedTech solutions in NHS, public #hospitals, #GeneralPractioner/ #Physician #Surgeries, #Pharmacies (despite proven Heath economics data & cost savings) & #regulatory uncertainty challenges ! To top it all, reluctance to #invest in such products by #investors exists, who avoid the #risks of potential adoption despite knowing the global AMR problem needs addressing. Thus, this invitation is crucial in the ‘#WorldAntiMicrobialResistanceAwarenessWeek (#WAAW)’, 18-24 Nov 2024. #AMR is a #healthcare problem, that affects everybody & every disease area- right from #cancers to #cardiology combined #deaths. An engaging discussion. Thank you to ‘#CPPG on #LifeSciences’ Members at The Scottish Parliament: #KennethGibson, MSP, Graham Simpson, Jackie Baillie, Michael Marra MSP, Brian Whittle OLY & The Association of the British Pharmaceutical Industry (ABPI), Alison Culpan FRSE, #ClaireHeadspeath for kind invitation. Enjoyed the presentations & discussions with #DeborahWilliamson, Till Bachmann & Tim Aitman. #DiagnosingBeforePrescribing Neil Gray, Caroline Lamb

88

7 Comments

When we set out to create the latest series of 5 Minute Jargon Busters, I was as keen as anyone to properly understand some of the terminology that has made its way into common use without necessarily being clearly understood. After all, buzzwords are my kryptonite - it's no surprise however that Hannah Mofeez Croft has managed to break down a vast and complex topic such as #syntheticbiology into a clear and engaging summary! Please read, share and comment Institution of Engineering and Technology (IET) Work Experience Cardiff University

17

3 Comments

Hi LinkedInVerse, Interested to get people's thoughts on this news story? As many in the Medical Devices, Biotech and Drug Discovery sectors has noticed over the last year, funding/investments have not been released, even when promised and contracts signed. I've noticed a little upturn in roles recently, which hopefully means funding/investments are now being released, is this other people's recent experience? I wish any of the political parties were talking more specifically about this, and hopefully this think tank may make them do this. https://lnkd.in/eizJ6s9Q #Investment #MedicalDevices #Biotech #DrugDiscovery IPPR #TheInstituteforPublicPolicyResearch

2

Accelerating Regulatory Submissions in Life Sciences with Generative AI As the complexity and volume of regulatory requirements in Life Sciences and Biotech continue to grow, there’s a pressing need for innovative solutions to synthesize and manage complex information efficiently. In this latest article by our Life Sciences Leader, Nicole Mather, we explore how IBM is leveraging Generative AI and automation to transform regulatory processes. Through a collaboration with Microsoft AI Studio, we’ve developed a Multi-Agent system—a network of digital agents working together to streamline content creation for complex clinical documents. This system generates a 75-90% complete first draft in minutes instead of hours, helping teams save time while ensuring accuracy and maintaining compliance—all within a secure and controlled environment. Find out more about this exciting collaboration here ➡️ https://lnkd.in/djydZMnp

36

5 Comments

#Biotech #BiosecureAct #USDefenseBill #ChinaBiotech #Biopharma The Biosecure Act, aimed at restricting U.S. pharmaceutical companies from collaborating with certain Chinese firms, has faced significant legislative challenges recently. The latest update on the legislative move regarding the inclusion of the BIOSECURE Act in the National Defense Authorization Act (NDAA) for fiscal year 2025 indicates that the BIOSECURE Act was NOT INCLUDED in the final version of the NDAA compromise. Negotiators decided against adding the BIOSECURE Act to the defense bill, which has effectively dealt a significant blow to its chances of enactment this year. Legislative Status : House Approval: The Biosecure Act was passed by the U.S. House of Representatives in September 2024, gaining substantial bipartisan support Senate Developments: Despite its passage in the House, the Act was notably excluded from the National Defense Authorization Act (NDAA) for fiscal year 2025 during recent negotiations, which has raised concerns about its future2411. This exclusion indicates a potential softening of the U.S. stance towards Chinese biotech firms, as it would have imposed restrictions on five specific companies linked to China Future Prospects : Alternative Strategies: Representative Brad Wenstrup, a key sponsor of the bill, indicated that there are alternative strategies for advancing the legislation, such as introducing it as a standalone measure in future sessions. However, analysts suggest that this route may be less favorable given the current political climate Support and Opposition: While there remains strong bipartisan support for some form of the Biosecure Act, opposition from certain Democratic lawmakers has complicated its path forward. Concerns have been raised regarding the potential negative impact on U.S. pharmaceutical research and development due to reliance on Chinese companies in supply chains. Currently, the Biosecure Act is not included in any major legislative package and its future remains uncertain. While there is a possibility for it to be reintroduced or attached to other legislation, significant obstacles exist that could hinder its passage in the near term. Thanks to Perplexity and Grok for the information. https://lnkd.in/gx8PJ6cF

1

Quick recap on what happened at the end of last week and over the weekend in biotech and pharma TLDR Biotech. If you want these story round-ups straight to your inbox (saving you time from sifting through a dozen+ news emails), hi the subscribe link below. #tldrbiotech #pharmanews #biotechnews

4

Hot on the heels of a post that acknowledges the ACI's announcement that the CMC has launched a taskforce to manage the TIGRR report comes one about the current managers of the intention of the report itself, the Department for Business and Trade (DBT). In January, I've been waiting for them to respond to the FOI below, but I've had delays, and on three occasions now, I've had to contact after they've missed deadlines as set in the FOIA. They seem to be searching avidly for exemptions to that FOI, but that's since January, and you'd think that by law, they 'should' have responded by now. And I know that they're following that law, see recently, they refused a series of further FOI's because all of them focused on CBD and novel foods whilst naming companies who're in the inner circle. The real reason I feel they refused them, and are seriously delaying the response to the FOI below, is because they don't want to expose any hand that they have in novel foods. That's too late though. I see them at CoT meetings from the very first time that CBD was discussed, I've seen the FSA asking all Local Authorities to send them 'CBD market data', I see their management of TIGRR, and I see that they have named GW in documents related to that management. I also saw when they released the Government Chemists report that suggested all 12 controlled cannabinoids should fall collectively inside MoDR's 1mg rule, and I see they have monitored public and private funding in GW, and that they have a further interest in what GW itself invests in. And for all those who are thinking "Don't you mean Jazz?", well DBT said they had information on GW from the point that they opened in 2023 until the 08 of January, which is well after Jazz brought them. For along time now, I've said that novel foods is being managed, and not by the FSA. In fact, they were shocked when I told them that in March this year. The proof is in the TIGRR Report, and the TIGRR report is being managed by DBT. Further more, the intent of the report isn't so much to make the UK a powerhouse for medicinal CBD and cannabinoid-based products as it is to redefine supplemental products as medicinal, and that benefits the few more than the many. You can find out more about that in the post link in the comment section, which might give you more of a clue as to why the DBT are hesitant to respond appropriately to my FOI request.

15

3 Comments

Here is the CEO of TVG explaining more about the company's recent grant, interesting to learn more about vaccines generally given how central they have become to health: https://lnkd.in/enCFRNAu

5

1 Comment